Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer

Jing LI; Lei ZHENG; Yu GAO

doi:10.19401/j.cnki.1007-3639.2024.03.006

您当前的位置：

首页 >

文章列表页 >

Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer

Article | 更新时间：2025-12-31

- Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer
- China Oncology Vol. 34, Issue 3, Pages: 286-292(2024)
- 作者机构：
  
  哈励逊国际和平医院消化内科，河北衡水 053000
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.03.006
  CLC： R735.2
- Received：07 October 2023，
  
  Revised：2024-02-22，
  
  Published：30 March 2024
- 稿件说明：
移动端阅览
Jing LI, Lei ZHENG, Yu GAO. Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer[J]. China Oncology, 2024, 34(3): 286-292.
DOI：

Jing LI, Lei ZHENG, Yu GAO. Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer[J]. China Oncology, 2024, 34(3): 286-292. DOI： 10.19401/j.cnki.1007-3639.2024.03.006.

摘要

背景与目的：

曲妥珠单抗的耐药发生率相对较低，可以作为辅助治疗提高临床疗效，既往多用于治疗乳腺癌，在其他癌症中的应用研究较少。本研究旨在探讨曲妥珠单抗辅助改良DOF双周方案对顺铂耐药的胃癌患者血清肿瘤标志物和生存率的影响，以期为顺铂耐药的胃癌患者的临床治疗方式选择提供更多参考。

方法：

选择2017年1月—2019年1月哈励逊国际和平医院收治的80例顺铂耐药的胃癌患者作为研究对象，按随机数字表法均分为观察组和对照组，均接受改良DOF双周方案治疗，观察组在此基础上加上曲妥珠单抗辅助治疗。比较两组的血清肿瘤标志物[血清癌胚抗原（carcinoembryonic antigen，CEA）、糖类抗原19-9（carbohydrate antigen 19-9，CA19-9）、CA72-4

]

、血清新生血管标志物[血管内皮生长因子（vascular endothelial growth factor，VEGF）、色素上皮衍生因子（pigment epithelial derived factor，PEDF）、血管生成素-2（angiopoietin-2，Ang-2）

]

、生化指标[N端脑钠肽前体（N terminal pro B type natriuretic peptide，NT-proBNP）、天冬氨酸转氨酶（aspartate transaminase，AST）、血尿素氮（blood urea nitrogen，BUN）、丙氨酸转氨酶（Alanine aminotransferase，ALT）

]

、不良反应及生存率。本研究经哈励逊国际和平医院伦理委员会审查批准（编号：20160511）。

结果：

治疗后，两组的

CEA、CA19-9及CA72-4较治疗前下降，且观察组的CEA、CA19-9及CA72-4检测值均低于对照组，差异有统计学意义（

0.01）。治疗后，两组的VEGF、PEDF及Ang-2较治疗前下降，差异有统计学意义（

0.01）；两组治疗前后的VEGF、PEDF及Ang-2差异无统计学意义（

0.05）。两组治疗前后的NT-proBNP、AST、BUN及ALT差异无统计学意义（

0.05）。两组的乏力、胃肠道反应、骨髓抑制发生人数占比及不良反应总发生率差异无统计学意义（

0.05）。治疗后5年，观察组存活11例（27.5%），死亡29例（72.5%）；对照组存活3例（7.5%），死亡37例（92.5%），观察组的中位生存期为2年（95% CI：1.8 ~ 2.2），对照组的中位生存期为1年（95% CI：0.6 ~ 1.4），观察组1 ~ 5年存活率高于对照组，差异有统计学意义（log-rank

= 13.853，

= 0.001）。

结论：

在顺铂耐药胃癌患者的临床治疗中采用曲妥珠单抗辅助改良DOF双周方案能降低血清肿瘤标志物表达水平，提升患者的5年生存率，且用药安全性较高。

Abstract

Background and purpose:

Trastuzumab has a relatively low incidence of drug resistance

which can be used as an adjuvant treatment to improve clinical efficacy. It has been used to treat breast cancer in the past

but its application in other cancers has been less studied. This study aimed to explore the effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in cisplatin-resistant gastric cancer patients

in order to provide more references for the selection of clinical treatment methods for cisplatin-resistant gastric cancer.

Methods:

Eighty patients with cisplatin-resistant gastric cancer treated in Harison International Peace Hospital from January 2017 to January 2019 were selected as the study objects

and they were divided into observation group and control group according to random number table method. All of them received improved DOF fortnightly treatment

and trastuzumab adjuvant treatment was added to the observation group on this basis. The serum tumor markers [serum carcinoembryonic antigen (CEA)

carbohydrate antigen 19-9 (CA19-9)

CA72-4

]

serum neovascular markers [vascular endothelial growth factor (VEGF)

pigment epithelial derived factor (PEDF)

angiopoietin-2 (Ang-2)

]

biochemical i

ndicators [N-terminal pro B type natriuretic peptide (NT proBNP)

aspartate transaminase (AST)

blood urea nitrogen (BUN)

alanine aminotransferase (ALT)

]

adverse reactions and survival rate were compared between two groups. This study was approved by the Ethics Committee of Harison International Peace Hospital (number: 20160511).

Results:

After treatment

CEA

CA19-9 and CA72-4 in both groups decreased

and CEA

CA19-9 and CA72-4 levels were lower in the observation group than in the control group with statistical significance (

0.01). After treatment

VEGF

PEDF and Ang-2 in two groups decreased

and the difference was statistically significant (

0.01). The levels of VEGF

PEDF and Ang-2 were compared between the two groups before and after treatment

and there was no significant difference (

0.05). The levels of NT-proBNP

AST

BUN and ALT were compared between the two groups before and after treatment

and there was no statistically significant difference (

0.05). The number of patients with fatigue

gastrointestinal reaction and myelosuppression and the total incidence of adverse reactions were compared between the two groups

and there was no statistically significant difference (

0.05). At 5 years after treatment

11 cases (27.5%) survived and 29 cases (72.5%) died in the observation group. There were 3 cases (7.5%) of survival and 37 cases (92.5%) of death in the control group. The median survival was 2 years (95% CI: 1.8-2.2) in the observation group and 1 year (95% CI: 0.6-1.4) in the control group. The survival rate of 1-5 years was higher in the observation group than in the control group. The difference was statistically significant (log-rank

= 13.853

= 0.001).

Conclusion:

In the clinical treatment of cisplatin-resistant gastric cancer

trastuzumab assisted modified DOF fortnightly regimen suggests that it can reduce the

expression levels of serum tumor markers

improve the 5-year survival rate of patients

and has certain drug safety.

关键词

Keywords

references

ZHANG C , LI D N , YU R X , et al . Immune landscape of gastric carcinoma tumor microenvironment identifies a peritoneal relapse relevant immune signature [J ] . Front Immunol , 2021 , 12 : 651033 . DOI: 10.3389/fimmu.2021.651033 http://doi.org/10.3389/fimmu.2021.651033 https://www.frontiersin.org/articles/10.3389/fimmu.2021.651033/full https://www.frontiersin.org/articles/10.3389/fimmu.2021.651033/full

KANG Y K , CHIN K , CHUNG H C , et al . S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial [J ] . Lancet Oncol , 2020 , 21 ( 8 ): 1045 - 1056 . DOI: 10.1016/S1470-2045(20)30315-6 http://doi.org/10.1016/S1470-2045(20)30315-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204520303156 https://linkinghub.elsevier.com/retrieve/pii/S1470204520303156

皇甫娟 , 张强 , 魏祯瑶 , 等 . 基于p53介导自噬通路探讨臭椿酮对顺铂耐药胃癌细胞株耐药性的影响 [J ] . 现代药物与临床 , 2021 , 36 ( 6 ): 1112 - 1118 .

HUANGFU J , ZHANG Q , WEI Z Y , et al . Effect of ailanthone on cisplatin-resistant gastric cancer cell line based on p53-mediated autophagy pathway [J ] . Drugs Clin , 2021 , 36 ( 6 ): 1112 - 1118 .

陈延群 , 莫海云 . DOF方案与XELOX方案一线治疗进展期胃癌疗效对比 [J ] . 中华肿瘤防治杂志 , 2021 , 28 ( 10 ): 782 - 787 .

CHEN Y Q , MO H Y . Comparison of DOF regimen and XELOX regimen as first-line treatment in advanced gastric cancer patients [J ] . Chin J Cancer Prev Treat , 2021 , 28 ( 10 ): 782 - 787 .

SHITARA K , BANG Y J , IWASA S , et al . Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer [J ] . N Engl J Med , 2020 , 382 ( 25 ): 2419 - 2430 . DOI: 10.1056/NEJMoa2004413 http://doi.org/10.1056/NEJMoa2004413 http://www.nejm.org/doi/10.1056/NEJMoa2004413 http://www.nejm.org/doi/10.1056/NEJMoa2004413

JANJIGIAN Y Y , MARON S B , CHATILA W K , et al . First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial [J ] . Lancet Oncol , 2020 , 21 ( 6 ): 821 - 831 . DOI: S1470-2045(20)30169-8 http://doi.org/S1470-2045(20)30169-8

中国研究型医院学会消化道肿瘤专业委员会 , 中国医师协会外科医师分会多学科综合治疗专业委员会 . 胃肠间质瘤多学科综合治疗协作组诊疗模式专家共识 [J ] . 中国实用外科杂志 , 2017 , 37 ( 1 ): 39 - 41 .

Digestive Tumor Professional Committee of China Research Hospital Association , Multidisciplinary Comprehensive Therapy Professional Committee of the Surgical Branch of the Chinese Medical Association . Expert consensus on diagnosis and treatment mode of gastric cancer multidisciplinary comprehensive treatment collaboration group [J ] . Chin J Pract Surg , 2017 , 37 ( 1 ): 39 - 41 .

曹毛毛 , 李贺 , 孙殿钦 , 等 . 2000—2019年中国胃癌流行病学趋势分析 [J ] . 中华消化外科杂志 , 2021 , 20 ( 1 ): 102 - 109 .

CAO M M , LI H , SUN D Q , et al . Epidemiological trend analysis of gastric cancer in China from 2000 to 2019 [J ] . Chin J Dig Surg , 2021 , 20 ( 1 ): 102 - 109 .

LIOU J M , MALFERTHEINER P , LEE Y C , et al . Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus [J ] . Gut , 2020 , 69 ( 12 ): 2093 - 2112 . DOI: 10.1136/gutjnl-2020-322368 http://doi.org/10.1136/gutjnl-2020-322368 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-322368 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-322368

张维汉 , 杨昆 , 陈心足 , 等 . 规范化外科手术与多学科综合治疗对胃癌患者预后的影响:一项单中心队列研究报告 [J ] . 中华胃肠外科杂志 , 2020 , 23 ( 4 ): 396 - 404 .

ZHANG W H , YANG K , CHEN X Z , et al . Effect of standardized surgical treatment and multidisciplinary treatment strategy on the prognosis of gastric cancer patients: report of a single-center cohort study. [J ] . Chin J Gast S , 2020 , 23 ( 4 ): 396 - 404 .

艾克热木·玉苏甫 , 阿布都沙拉木·依米提 , 再依奴尔·阿不都外力 , 等 . 不同新辅助化疗方案治疗进展期胃癌的疗效和安全性及费用评估研究 [J ] . 中国全科医学 , 2020 , 23 ( 26 ): 3286 - 3290 . DOI: 10.12114/j.issn.1007-9572.2019.00.774 http://doi.org/10.12114/j.issn.1007-9572.2019.00.774

AIKEREMU·YUSUFU , ABUDUSHALAMU·YIMITI , ZAIYINUER·ABUDUWAILI , et al . Evaluation of safety, efficacy and hospitalization cost of three neoadjuvant chemotherapy regimens for advanced gastric cancer [J ] . Chin Gen Pract , 2020 , 23 ( 26 ): 3286 - 3290 .

MAKIYAMA A , SUKAWA Y , KASHIWADA T , et al . Randomized, phase Ⅱ study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study) [J ] . J Clin Oncol , 2020 , 38 ( 17 ): 1919 - 1927 . DOI: 10.1200/JCO.19.03077 http://doi.org/10.1200/JCO.19.03077 https://ascopubs.org/doi/10.1200/JCO.19.03077 https://ascopubs.org/doi/10.1200/JCO.19.03077

HACKSHAW M D , BUI C L , LADNER A , et al . Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumab [J ] . Cancer Treat Res Commun , 2020 , 24 : 100189 .

朱麒 , 肖瑶 , 金丽艳 , 等 . 曲妥珠单抗联合化疗对HER-2阳性胃癌患者T淋巴细胞亚群及肿瘤标志物的影响 [J ] . 临床肿瘤学杂志 , 2023 , 28 ( 2 ): 159 - 163 .

ZHU Q , XIAO Y , JIN L Y , et al . Effects of Trastuzumab combined with chemotherapy on T lymphocyte subsets and tumor markers in patients with HER-2 positive gastric cancer [J ] . Chin Clin Oncol , 2023 , 28 ( 2 ): 159 - 163 .

李红 , 史长山 . 曲妥珠单抗辅助治疗HER2阳性晚期胃癌的安全性及对患者血清肿瘤标志物的影响研究 [J ] . 长春中医药大学学报 , 2022 , 38 ( 1 ): 88 - 92 .

LI H , SHI C S . Safety of the trastuzumab adjuvant treatment of HER2-positive advanced gastric cancer and its effect on patients' serum tumor markers [J ] . J Changchun Univ Chin Med , 2022 , 38 ( 1 ): 88 - 92 .

Views

1974

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical significance of serum CEA, CA125 and CA72-4 in gastric carcinoma with peritoneal metastasis

Survival analysis of patients with gastric cancer in Shanghai

A study on the immunomicroenvironment characteristics of gastric cancer with neuroendocrine neoplasm and pure gastric cancer

Prospective trial on impact of oral nutritional supplements on elderly patients with nutritional risk after radical surgery for gastric cancer

Research progress and future perspectives of anticancer drug-induced interstitial lung disease/pneumonia in gastric cancer

Related Author

孙立秋

崔　海

崔　演

彭　鹏

吴春晓

龚杨明

ZHANG Yi

SUN Haidong

Related Institution

延边大学附属医院肿瘤科，延吉

上海市疾病预防控制中心肿瘤防治科

Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Gastrointestinal Surgery, General Surgery, Zhongshan Hospital, Fudan University

AI问答

⁰